ENZYME SUPPLEMENTATION THERAPY OF EXOCRINE PANCREATIC DEFICIENCY WITH PANCREATIN PREPARATIONS: RETROSPECTIVE PHARMACOECONOMIC STUDIES

In recent years, halenic forms of enzyme preparations were developed. These drugs substantively improve delivery, incorporation and interaction of proteases and lipases and their substrates, and significantly improve the quality of supplementation treatment of pancreatic deficiency. Constraining factor for widespread use of these drugs is relatively high cost compared with pelleted enteric-coated pancreatine; but the use of such pancreatine is substantially ineffective. The retrospective comparative study on model of complete inpatient event insurance for the diagnosis of chronic pancreatitis was conducted. The use of two different preparations of pancreatine with equivalent doses of lipase (Creon® and Mezym forte 10000) - not less than 100 000 units of lipase per day - was compared. Against the background of Creon administration, duration of the treatment period has decreased by 7 days that led to reduction of cost of inpatient treatment by one third. The cost ratio for pain relief and reduction of exocrine pancreatic deficiency with Creon showed savings in 542,21 and 355,82 rubles per patient, respectively. Thus, despite the higher cost of equivalent dose of lipase, supplementation treatment with Creon in patients with chronic pancreatitis with exocrine deficiency was proved to be more beneficial.

pancreatic deficiency, chronic pancreatitis, pancreatine, Creon®, pharmacoeconomic studies